NURIX THERAPEUTICS INC (NRIX)
US67080M1036 - Common Stock
Nurix Therapeutics Announces Upcoming Oral Presentation of New Data from Ongoing Clinical Trial of NX-5948, a Selective Bruton’s Tyrosine Kinase (BTK) Degrader, at the European Hematology Association Congress (EHA2024)
Overall response rate of 70% observed in 10 evaluable heavily pretreated CLL patients Data showcase deepening clinical responses with longer time on...
Nurix Therapeutics to Participate in RBC Capital Markets Global Healthcare Conference
SAN FRANCISCO, May 07, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted...
First Week of NRIX June 21st Options Trading
Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
SAN FRANCISCO, April 16, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced the closing of its underwritten public offering...
Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering
SAN FRANCISCO, April 11, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced the pricing of its upsized underwritten public...
Nurix Therapeutics Announces Proposed Public Offering
SAN FRANCISCO, April 11, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted...
NRIX Stock Earnings: Nurix Therapeutics Beats EPS, Misses Revenue for Q1 2024
NRIX stock results show that Nurix Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
NRIX Stock Earnings: Nurix Therapeutics Beats EPS, Misses Revenue for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Nurix Therapeutics (NASDAQ:NRIX) just reported results for the first quarter of...
Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update
Extended the Strategic Collaboration with Gilead Sciences Extended the Strategic Collaboration with Sanofi to Develop Novel Orally Available Targeted...
Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies
Presented new case studies demonstrating clinical responses in two patients with B cell malignancies, chronic lymphocytic leukemia (CLL) and primary...
Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6
Goal is to develop an oral STAT6 degrader investigational new drug with potential to address the needs of patients with type 2 inflammation Nurix...
Nurix Therapeutics to Participate in Upcoming Investor Conferences
SAN FRANCISCO, April 03, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted...
Commit To Purchase Nurix Therapeutics At $10, Earn 18.3% Annualized Using Options
Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences
Two-year extension of ongoing research collaboration intended to generate multiple additional clinical candidates Nurix will receive a $15.0 million...
Nurix Therapeutics is Part of a Team of International Oncology Experts Selected as Cancer Grand Challenges Awardees to Address Pediatric Cancers Using Targeted Protein Degradation (TPD)
Researchers will apply the latest TPD drug discovery technology to target fusion proteins that cause pediatric cancer Cancer Grand Challenges is an...
Nurix Presents the Discovery and Chemical Structure of First-in-Class CBL-B Inhibitor NX-1607 at the American Chemical Society (ACS) Meeting
Disclosure of the discovery and structure of NX-1607, the first inhibitor of CBL-B to advance into clinical studies. ...
Nurix Therapeutics to Participate in Upcoming Investor Conferences
Nurix Therapeutics to participate in March investor conferences...
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides a Corporate Update
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides a Corporate Update...
Nurix Therapeutics Announces Publication in the Journal Science Identifying a New Class of BTK Mutations That Are Susceptible to NX-2127, a Novel BTK and IKZF1/3 Degrader
Data reveal oncogenic scaffold function of BTK mutations that lack kinase activity and show these mutations remain susceptible to degradation by NX-2127 ...
Nurix gets fast track status for leukemia drug candidate (NASDAQ:NRIX)
Nurix Therapeutics (NRIX) has received FDA fast track designation for its leukemia drug candidate NX-5948. Read more here.
Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory CLL and SLL
Fast track designation follows positive Phase 1 data presented at the American Society of Hematology that supports strategy to broadly develop NX-5948 in...
NRIX Crosses Below Key Moving Average Level
Nurix Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
SAN FRANCISCO, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted...
Commit To Purchase Nurix Therapeutics At $7.50, Earn 23.6% Annualized Using Options
